Data on this page show the responses of parents and carers of individuals aged 6 months to younger than 5 years who received a standard influenza vaccine and completed an AusVaxSafety survey sent in the days following vaccination. Standard influenza vaccines currently in use in this age group include Vaxigrip Tetra®, Fluarix Tetra®, FluQuadri®, Influvac® Tetra and Flucelvax® Quad. These data provide you with a profile of what to expect in the days following your influenza vaccination and can assist when planning for your influenza vaccination.

AusVaxSafety surveillance of 2023 seasonal flu vaccines has concluded with no safety issues identified. Recommencement of surveillance will coincide with the release of 2024 seasonal influenza vaccines.


AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities.

Links to further information on the influenza vaccines are available below:

Last updated September 2023